**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a retrospective study of patients admitted in Wuhan, China, 10 patients (8 men and 2 women) aged 24−65 years were described, who developed COVID-19 pneumonia during immunosuppressive treatment with tacrolimus, mycophenolate mofetil, prednisolone, ciclosporin or mizoribine.

The patients, who had undergone kidney transplantation, had been receiving immunosuppressive treatment with tacrolimus, mycophenolate mofetil and prednisolone (7 patients), tacrolimus and mycophenolate mofetil (2 patients), and ciclosporin and mizoribine (1 patient) \[*dosages and routes not stated*\]. Of the 10 patients, 6 patients also had underlying co-morbidities, which were: chronic coronary disease, chronic heart failure and atrial fibrillation (1 patient), hypertension (3 patients), hypertension and chronic coronary disease (1 patient), and hypertension, hypertensive heart disease and chronic obstructive pulmonary disease (1 patient). Two of them had travelled to Wuhan. Between 17 January 2020 to 3 February 2020, the patients presented with symptoms of fever, cough, shortness of breath, fatigue and diarrhoea (3 patients), fever, cough, shortness of breath and fatigue (5 patients), fever (1 patient), and cough, shortness of breath and fatigue (1 patient). The patients had fever since 3−13 days. The SARS-Cov-2 test resulted positive in all the ten patients. Laboratory tests revealed elevated CRP and serum creatinine (1 patient), elevated CRP, elevated serum creatinine and lymphopenia (3 patients), elevated CRP, elevated ALT and lymphopenia (2 patients), elevated CRP and lymphopenia (1 patient), elevated CRP and ALT (1 patient), and elevated CRP, lymphopenia, elevated serum creatinine and elevated ALT (2 patients). Based on the chest CT scan and other findings, the patients were diagnosed with COVID-19 pneumonia after 2−26 days of the symptom onset. The infection was mild in 2 patients, severe in 5 patients and critical in 3 patients. After 4−27 days of the symptom onset, the patients were admitted to a hospital in China. It was determined that the post-transplant long-term immusuppressive therapy might have contributed to the COVID-19 pneumonia \[*durations of treatments to reactions onsets not stated*\].

The treatment with mycophenolate mofetil, mizoribine, tacrolimus or ciclosporin was stopped in 9 patients for 6−30 days, and the dose of tacrolimus was reduced in 1 patient. Tacrolimus and ciclosporin were gradually re-initiated at a reduced dose in seven of the 10 patients. Nine of the 10 patients were treated with methylprednisolone and immune globulin (6 patients), methylprednisolone (2 patients), and immune globulin (1 patient). Additionally, the patients received unspecified antiviral treatment, and received oxygen via nasal catheter to maintain oxygen saturation \>95%. Three of the 10 patients required non-invasive mechanical ventilation for 1−3 days due to disease progression. Eight of the 10 patients recovered and were discharged after total 13−43 days of the hospital stay. Of the remaining 2 patients, one patient showed significant improvement in the pneumonia after approximately 45 days of hospital stay, and was kept under observation due to the recent positive result from a nucleic acid test for SARS-CoV-2. The other patient experienced an acute renal allograft failure, and died due to sudden acute respiratory failure on day 6 of the admission.
